Anne Dejean

Anne Dejean

Auto-generated profile, based on publicly available information

Anne Dejean

Institut Pasteur, Université Paris Cité, Nuclear Organization and Oncogenesis Unit, Paris, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Pascal PineauPascal Pineau
Pascal Pineau
Stefano VoliniaStefano Volinia
Stefano Volinia
KMKatherine McJunkin
Katherine McJunkin
AMAgnès Marchio
Agnès Marchio
CBCarlo Battiston
Carlo Battiston
ADAnne Dejean
Anne Dejean
MicroRNA (miRNAs) are negative regulators of gene expression and can function as tumor suppressors or oncogenes. Expression patterns of miRNAs and their role in the pathogenesis of hepatocellular carcinoma (HCC) are still poorly understood. We profiled miRNA expression in tissue samples (104 HCC, 90 adjacent cirrhotic livers, 21 normal livers) as well as in 35 HCC cell lines. A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC. miR-221/222, the most up-regulated miRNAs in tumor samples, are shown to target the CDK inhibitor p27 and to enhance cell growth in vitro. Conversely, these activities can be efficiently inhibited by an antagomiR specific for miR-221. In addition, we show, using a mouse model of liver cancer, that miR-221 overexpression stimulates growth of tumorigenic murine hepatic progenitor cells. Finally, we identified DNA damage-inducible transcript 4 (DDIT4), a modulator of mTOR pathway, as a bona fide target of miR-221. Taken together, these data reveal an important contribution for miR-221 in hepatocarcinogenesis and suggest a role for DDIT4 dysregulation in this process. Thus, the use of synthetic inhibitors of miR-221 may prove to be a promising approach to liver cancer treatment.

30 January 2017 in Nature Reviews Cancer
Verified
Journal Article
Closed access
JSJacob-Sebastian Seeler
Jacob-Sebastian Seeler
ADAnne Dejean
Anne Dejean

26 February 2012 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MBMoussa Benhamed
Moussa Benhamed
UHUtz Herbig
Utz Herbig
TYTao Ye
Tao Ye
ADAnne Dejean
Anne Dejean
OBOliver Bischof
Oliver Bischof

14 December 2015 in Nature Immunology
Verified
Journal Article
Closed access
ADAdrien Decque
Adrien Decque
OJOlivier Joffre
Olivier Joffre
JMJoao G Magalhaes
Joao G Magalhaes
JCJack-Christophe Cossec
Jack-Christophe Cossec
RBRonnie Blecher-Gonen
Ronnie Blecher-Gonen
ADAnne Dejean
Anne Dejean

1 November 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
JCJack-Christophe Cossec
Jack-Christophe Cossec
ITIlan Theurillat
Ilan Theurillat
CCClaudia Chica
Claudia Chica
SASabela Búa Aguín
Sabela Búa Aguín
XGXavier Gaume
Xavier Gaume
ADAnne Dejean
Anne Dejean

26 July 2013 in Genome Research
Verified
Journal Article
Open access
PDF file
HNHélène NEYRET-KAHN
Hélène NEYRET-KAHN
MBMoussa Benhamed
Moussa Benhamed
TYTao Ye
Tao Ye
SGStéphanie Le Gras
Stéphanie Le Gras
JCJack-Christophe Cossec
Jack-Christophe Cossec
ADAnne Dejean
Anne Dejean
Despite numerous studies on specific sumoylated transcriptional regulators, the global role of SUMO on chromatin in relation to transcription regulation remains largely unknown. Here, we determined the genome-wide localization of SUMO1 and SUMO2/3, as well as of UBC9 (encoded by UBE2I) and PIASY (encoded by PIAS4), two markers for active sumoylation, along with Pol II and histone marks in proliferating versus senescent human fibroblasts together with gene expression profiling. We found that, whereas SUMO alone is widely distributed over the genome with strong association at active promoters, active sumoylation occurs most prominently at promoters of histone and protein biogenesis genes, as well as Pol I rRNAs and Pol III tRNAs. Remarkably, these four classes of genes are up-regulated by inhibition of sumoylation, indicating that SUMO normally acts to restrain their expression. In line with this finding, sumoylation-deficient cells show an increase in both cell size and global protein levels. Strikingly, we found that in senescent cells, the SUMO machinery is selectively retained at histone and tRNA gene clusters, whereas it is massively released from all other unique chromatin regions. These data, which reveal the highly dynamic nature of the SUMO landscape, suggest that maintenance of a repressive environment at histone and tRNA loci is a hallmark of the senescent state. The approach taken in our study thus permitted the identification of a common biological output and uncovered hitherto unknown functions for active sumoylation at chromatin as a key mechanism that, in dynamically marking chromatin by a simple modifier, orchestrates concerted transcriptional regulation of a network of genes essential for cell growth and proliferation.